Researchers developed a technique that uses infrared light and machine learning to determine the sex of blow fly larvae, improving time-of-death estimates. The method achieved over 90% accuracy and has potential applications in forensic entomology, agriculture, and biosecurity.
A novel antibody-drug conjugate iza-bren demonstrated an objective response rate of 66.0% and a confirmed ORR of 56.0% in EGFR-mutated NSCLC patients, with manageable safety profile. The median progression-free survival was 12.5 months.
A combination of iza-bren and osimertinib demonstrated a 100% objective response rate in patients with first-line EGFR-mutated locally advanced or metastatic non-small cell lung cancer. The regimen was also manageable from a safety perspective, with most treatment-related adverse events being hematologic.
The COMPEL trial demonstrates that patients with EGFR-mutated advanced non-small cell lung cancer benefit from continued osimertinib treatment in combination with platinum-based chemotherapy. This approach is associated with improved progression-free survival and overall survival compared to placebo plus chemotherapy.
The CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life in patients with resectable non-small cell lung cancer, including those with Stage III N2 disease. Nivolumab also reduces risk of symptom deterioration in these high-risk patients.
A new study validates the use of Sybil, a deep learning artificial intelligence model, for predicting future lung cancer risk in a predominantly Black population. The model demonstrated high predictive accuracy for lung cancer risk up to six years after a single low-dose CT scan.
The study found that adding baxdrostat to standard care can lower blood pressure and delay kidney damage in patients with chronic kidney disease and uncontrolled high blood pressure. Participants experienced a significant reduction in urine albumin levels, indicating potential benefits for delaying kidney progression.